Britain and America have forged a major commercial pact that will maintain no duties on British pharmaceutical shipments entering the US market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has pledged to boost spending on drugs through the National Health Service (NHS). This move ensures that import taxes on these key exports will be held at nothing for a period of the next three years.
This agreement comes after recent statements to significantly raise tariffs on patented drug imports, with potential rates discussed up to 100%.
"This agreement between the Britain reinforces the international landscape for cutting-edge drugs and introduces much-needed balance to transatlantic pharmaceutical trade," a statement declared.
Trade Impact
Drugs represent one of the Britain's biggest goods shipped to the United States, which is easily the largest market for large British pharmaceutical firms.
Trade data indicate that in the 12 months to the end of September, the UK sold pharmaceutical products worth £11.1bn to the US. This figure represented a significant portion of total UK exports in that span.
"This guarantee protects employment, increases funding and paves the way for the UK to emerge as a global hub for medical research," a minister stated.
Key British Pledges
The deal entails several specific pledges from the UK:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it considers new medicines to be too expensive by a quarter.
- Higher Drug Budget: There is a aim to double overall public funding on treatments from 0.3 percent of GDP to 0.6% over the next decade.
- Refund Ceiling: The amount manufacturers must refund to the NHS to stay within budget will be restricted at fifteen percent. Previously, refunds topped 20%.
Industry Background
The deal follows a protracted row between the pharmaceutical industry and the British authorities over spending levels and NHS adoption.
This friction were heightened by claims that American patients were charged several times more for the equivalent treatments than people in the Britain and the EU.
In recent months, several major drug company projects in the UK have been paused or abandoned, while major investments have been pledged toward projects in the United States.
A senior figure stated that the NHS needed to invest a greater share on drugs, noting that its spending on drugs had decreased as a share of its resources over the last ten years.
